Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MRUS

MRUS - Merus NV Stock Price, Fair Value and News

$90.00 
Market Closed

Price Targets

MRUS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MRUS Price Action

Last 7 days

-7.1%

Last 30 days

-6.4%

Last 90 days

-4.5%

Trailing 12 Months

112.8%

MRUS RSI Chart

MRUS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MRUS Valuation

Market Cap

6.8B

Price/Earnings (Trailing)

-17.91

Price/Sales (Trailing)

120.59

EV/EBITDA

-17.57

Price/Free Cashflow

-21.47

MRUS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

MRUS Fundamentals

MRUS Revenue

Revenue (TTM)

56.6M

Rev. Growth (Yr)

3.21%

Rev. Growth (Qtr)

37.63%

MRUS Earnings

Earnings (TTM)

-381.1M

Earnings Growth (Yr)

4.39%

Earnings Growth (Qtr)

39.63%

MRUS Profitability

EBT Margin

-653.35%

Return on Equity

-49.18%

Return on Assets

-42.15%

Free Cashflow Yield

-4.66%

MRUS Investor Care

Shares Dilution (1Y)

10.78%

Diluted EPS (TTM)

-5.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202554.7M56.2M56.6M0
202438.3M35.2M35.9M36.1M
202343.4M41.2M45.7M43.9M
202252.4M52.7M45.6M41.6M
202132.0M38.3M43.4M49.1M
202028.6M28.3M28.7M29.9M
201936.6M34.8M32.9M31.1M
201826.0M30.1M34.3M38.4M
20177.4M12.2M17.1M21.9M
20160002.5M
20150001.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Merus NV

MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
 CEO
 WEBSITEmerus.nl
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES164

Merus NV Frequently Asked Questions

MRUS is the stock ticker symbol of Merus NV. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jan 02 2026, market cap of Merus NV is 6.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jan 02 2026, MRUS's PE ratio (Price to Earnings) is -17.91 and Price to Sales (PS) ratio is 120.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRUS PE ratio will change depending on the future growth rate expectations of investors.